Drug application
CABAZITAXEL (CABAZITAXEL)
Drugs@FDA NDA 207937 · FRESENIUS KABI USA
Key facts
| Drug name | CABAZITAXEL |
|---|---|
| Active ingredients | CABAZITAXEL |
| Application type | NDA |
| Application number | 207937 |
| Company | FRESENIUS KABI USA |
| Dosage forms | INJECTABLE, INJECTION |
| Strength | 20MG/ML |
| Marketing status | None (Tentative Approval) |
| Reference listed drug | No |
| Latest submission class | Type 5 - New Formulation or New Manufacturer |
| Latest submission status date | Nov 22, 2019 |
At a glance
- 1–9 Submissions
- 1–9 Supplements
- None Label versions
- 1–9 Products
- None Therapeutic equivalents
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Drugs@FDA applications
Drugs@FDA covers FDA-approved brand-name and generic drugs and therapeutic biologics, with their applications (NDA, ANDA or BLA), products, submissions and labels.
Source: U.S. Food and Drug Administration (FDA), Drugs@FDA · Source date: